Drug Trial Radar · NCT05669950
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Dec 19, 2022
Primary completion
Sep 30, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- H. Lundbeck A/SIndustry
- Sponsor type
- Industry
- First posted
- Jan 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.
Conditions
- Congenital Adrenal Hyperplasia
Interventions
Lu AG13909Drug
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Day 161
- Parts A and B: Number of Participants With Anti-Drug Antibodies (ADAs)Time frame: Day 1 up to Day 161
- Parts A and B: Cmax: Maximum Observed Serum Concentration of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
- Parts A and B: Tmax: Nominal Time Corresponding to the Occurrence of CmaxTime frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
- Parts A and B: Ctrough: Minimum Observed Serum Concentration of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
- Parts A and B: t½: Apparent Elimination Half-life of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
- Parts A and B: AUC0-infinity: Area under the plasma concentration curve of x from zero to infinity of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
- Parts A and B: CL: Apparent Total Serum Clearance of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
- Parts A and B: Vz: Volume of Distribution During the Terminal Elimination Phase After IV Administration of Lu AG13909Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
- Parts A and B: Change From Baseline After Each Dose of Lu AG13909 in Blood Concentrations of 17-hydroxyprogesterone (17-OHP) and Androstenedione (A4)Time frame: Baseline up to Day 85
- Parts A and B: AUC0-tau: Area under the curve over a dosing intervalTime frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161
- Part C: Morning Concentration of A4 in Blood <Upper Limit of Normal (ULN)Time frame: Day 169
Locations
17 sites in 9 countries. Site status is shown where the registry gives one.
University Hospital-University of Michigan
Ann Arbor, Michigan · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
Chu Angers
Angers, France · Recruiting
CHU de Lille
Lille, France · Recruiting
GH Pitié-Salpêtrière
Paris, France · Recruiting
CHRU Strasbourg
Strasbourg, France · Recruiting
David Metreveli Medical Centre, Tbilisi
Tbilisi, Georgia · Recruiting
Beaumont Hospital Royal College of Surgeons in Ireland (RCSI), Dublin
Dublin, Ireland · Recruiting
Azienda Ospedaliero Universitaria di Bologna
Bologna, Italy · Recruiting
Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma
Roma, Italy · Recruiting
Centrum Nowoczesnych Terapii, Dobry Lekarz
Dobry Lekarz, Poland · Recruiting
Sahlgrenska University Hospital
Gothenburg, Sweden · Recruiting
Karolinska University Hospital
Stockholm, Sweden · Recruiting
NIHR/Wellcome Trust Clinical Research Facility
Birmingham, United Kingdom · Recruiting
Cambridge Clinical Research Centre
Cambridge, United Kingdom · Recruiting
NIHR Clinical Research Facility
London, United Kingdom · Recruiting
University College London Hospital - NIHR
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.